An Update from Our Firm about COVID-19

Abraham, Watkins, Nichols, Sorrels, Agosto, Aziz & Stogner remains fully operational and committed to serving our clients and colleagues throughout the Coronavirus (COVID-19) crisis. As we follow the CDC guidelines and practice social distancing, we remain available for phone consultations and scheduled in-person meetings with both current and prospective clients and colleagues. Please contact our office by email or by calling 713-222-7211 with any questions. We look forward to hearing from you.

Congress Looks to Strengthen Regulation of Compounding Pharmacies

In the wake of a recent deadly meningitis outbreak, the Senate Health, Education, Labor and Pensions (HELP) Committee will consider ways to strengthen regulation of drug compounding.

The issue is on Congress's radar as a result of the meningitis outbreak that has killed 53 people and sickened more than 700 since September. It has become clear to Congress that regulation has not kept pace with the fast-growing sector of the drug industry that makes batches of commonly used combination drugs for clinics and hospitals nationwide. The outbreak was caused by a negligent drug compounder, the now-shuttered New England Compounding Center (NECC), which created and shipped custom medications in large quantities.

The Food and Drug Administration (FDA) has called on Congress to clarify its authority to regulate non-traditional drug compounders like the NECC, and lawmakers in both chambers are debating paths forward.

The Senate HELP Committee, which will hold a hearing Thursday, released a draft bill last month that would create a new category of large sterile compounding facilities which would have to register with the Food and Drug Administration and be subject to agency inspection and oversight.

That oversight would be slightly less stringent than the type faced by full-scale drug manufacturers, which have to meet the highest FDA standards, but more stringent than those governing traditional community compounders, which are regulated by state boards of pharmacy.

If you or someone you know has been harmed by a medication, contact the attorneys at Abraham, Watkins, Nichols, Sorrels, Agosto & Friend by calling 713-396-3964 or 1-800-594-4884.

No Comments

Leave a comment
Comment Information
  • $50+ Million Fire & Explosion

    The firm successfully represented nearly 100 victims who suffered personal injuries and damages to property from a large fire and explosion resulting in a settlement of more than $50 million. The firm served as lead lawyers on the steering committee in this litigation.

  • $80 Million Plant Explosion

    The firm successfully represented 270 plaintiffs, taking a lead role in the plaintiffs’ steering committee, who suffered injuries in a large plant explosion resulting in a settlement of nearly $80 million.

  • $50+ Million Plant Fire & Explosion

    The firm successfully represented 45 personal injury victims in a plant fire and explosion, serving on the plaintiffs steering committee, concluding with a settlement of more than $50 million.

  • $22+ Million Worksite Accident

    The firm prevailed in a personal injury trial for a worksite injury client with the jury returning a verdict and resulting in a judgment of over $22 million for the firm’s client.

  • $12 Million 18-Wheeler Collision

    The firm successfully achieved a $12 million settlement for the family of a man who died in an 18 wheeler collision.

  • $48 Million Catastrophic Burns

    The firm prevailed on behalf of three burn victims with settlements totaling nearly $48 million.

Our Record Of Success

When you are hurt and you choose a law firm to represent you in court or at the negotiation table, you need to carefully consider the firm's record.

Read More Success Stories

Let Us Help You Request a Free Consultation Today

Get Help Now

Bold labels are required.

Contact Information
disclaimer.

The use of the Internet or this form for communication with the firm or any individual member of the firm does not establish an attorney-client relationship. Confidential or time-sensitive information should not be sent through this form.

close

Privacy Policy

Back to top